Le Lézard

News by subject: TRI

1 2 3 4 5 6 7 8 9 10

18 april 2019

11:12
Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), announced that Drs. Paul Martin and Kevin Flanigan from the Research Institute at Nationwide Children's Hospital have...

09:30
TAU BIO-LOGIC CORP. announced today that in collaboration with the UK-based group LifeArc, it has successfully humanized a monoclonal antibody (TBL-100) that targets C-terminally truncated tau (tauC3).  TAU BIO-LOGIC is developing TBL-100 for the...

09:00
Columbia University and Project ALS today announced the Project ALS Therapeutics Core at Columbia, a 3-year, $6.3M initiative toward the first meaningful therapies for ALS. The Core is the world's first and only partnership between a world-class...

09:00
TriNetX, the global health research network that optimizes clinical research and enables discoveries through the generation of real-world evidence (RWE), today announced that the Journal of Clinical Hypertension has published its article on an...

09:00
Whether Mr. Right hasn't appeared "in time" or a long-held desire to become a mother blends with an independent lifestyle, single women today have an amazing array of fertility options to forge their own path to parenthood, according to fertility...

08:45
Ongoing PRO Study, REMfresh® Duration VALidation (REMVAL), will be analyzed upon study completion to assess improvement in sleep duration, onset, maintenance, quality and patient satisfaction in a general patient population. A second, ongoing study,...

08:00
Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF), today...

08:00
Soliton, Inc. ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that its...

07:00
A major milestone on its strategic mission to lead in sepsis diagnostics, Beckman Coulter today announced that its Early Sepsis Indicator has received 510(k) clearance from the U.S. Food and Drug Administration. Sepsis is a global healthcare crisis...

07:00
Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has reached a significant...

07:00
MicroVention, Inc., a U.S.-based subsidiary of Terumo Corporation and a global neurovascular company, announced today the publication of the WEB-IT pivotal trial results in the online edition of the Journal of NeuroInterventional Surgery. The WEB®...

06:47
Genesis Innovation Group's Shoulder Innovations (SI) is focused on human centered design.  Stephen Gunther, M.D., from Charlottesville, VA and the team at Shoulder Innovations have developed an innovative solution for the glenoid, called the InSettm...

06:00
Bioclinica®, a leading provider of science and technology expertise to assist the life science industry in advancing the development of medical therapies, announced today that it has assembled a team of experts dedicated to nonalcoholic fatty liver...

03:35
Cantargia AB today announce that the phase I clinical data generated by the antibody CAN04 will be presented orally at the 2019 Annual ASCO meeting May 31 ? June 3, 2019 in Chicago. The coordinating investigator Prof Ahmed Awada will present the data...


17 april 2019

17:02
Gene therapy developed at St. Jude Children's Research Hospital has cured infants born with X-linked severe combined immunodeficiency (SCID-X1). The children are producing functional immune cells, including T cells, B cells and natural killer (NK)...

17:00
United BioPharma (UBP) today announced that its monoclonal antibody product, UB-421, is able to suppress HIV for at least four months in patients who previously paused their antiretroviral therapy (ART) regimen. The results of the study were...

14:24
Using CRISPR gene editing, a team from Children's Hospital of Philadelphia (CHOP) and Penn Medicine have thwarted a lethal lung disease in an animal model in which a harmful mutation causes death within hours after birth. This proof-of-concept study,...

12:40
The Background In 2016, FightMND helped to support the phase 1 clinical trial of CuATSM where it was given to MND patients as a therapeutic for the first time. The primary objective, as per any phase 1 trial, was to assess safety and tolerability of...

12:00
Stealth BioTherapeutics, a clinical-stage biotechnology company focused on novel therapies for diseases involving mitochondrial dysfunction, announced yesterday at the 2019 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference...

10:53
The Journal of General Internal Medicine published a new National Kidney Foundation (NKF) study describing key challenges in primary care practitioners (PCPs) and nephrologists working together to care for patients with chronic kidney disease (CKD)....

10:00
Quartesian LLC, a full-service contract research organization (CRO) providing data management, biostatistics, and other services to clinical trial sponsors, has entered into a multi-year agreement with Medrio, a leading provider of eClinical...

09:00
Researchers and scientists are constantly developing new, innovative medicines to effectively treat patients. However, the cost to conduct clinical trials and then receive approval to commercialize a drug is absurdly expensive. The Tufts Center for...

09:00
Cannabics Pharmaceuticals Inc. , a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has obtained approval for a nationwide Israeli multisite clinical study on the antitumor properties of...

08:27
Aethlon Medical, Inc. , today released the following shareholder update authored by its CEO, Timothy C. Rodell, M.D. To Aethlon Medical, Inc. Shareholders: In December of last year, Aethlon completed a restructuring of...

08:00
OncoSec Medical Incorporated (OncoSec) , a company developing intratumoral cancer immunotherapies, and Duke University School of Medicine, today announced that they have entered into a collaborative research agreement to evaluate the use of OncoSec's...

07:50
Neovasc Inc. ("Neovasc" or the "Company") , a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today...

07:30
Moleculin Biotech, Inc., ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that its ongoing sponsored research at The University of...

07:00
In the latest peer-reviewed published study on the impact of decreasing blood culture contamination rates using Steripath® ISDD®, researchers at Massachusetts General Hospital, Harvard Medical School and Wing Tech Inc. have concluded that both...

07:00
Senhwa Biosciences, Inc. (TPEx: 6492) announced today that the clinical trial of Silmitasertib (CX-4945) for the treatment of Basal Cell Carcinoma (BCC) has enrolled its first patient at Texas Oncology, Texas, USA. The trial will be carried out...

05:00
Clinical trials take a group of individuals and evaluate how certain treatment effects them. Data is collected and analyzed to then determine educated findings and results. It's crucial to keep patients involved during clinical trials, as otherwise,...

02:25
Significant events January-March First patient dosed in Phase I clinical study of ATOR-1015. New preclinical data presented demonstrating strong anti-tumor effects for the 4-1BB antibody ATOR-1017. Alligator Bioscience launched RUBYtm, a novel...


16 april 2019

20:00
Bioelectronic medicine scientists at The Feinstein Institute for Medical Research collaborated with counterparts from Academic Medical Center at University of Amsterdam in the Netherlands to carry out a series of pilot clinical studies to assess the...

18:01
Stealth BioTherapeutics , a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced positive results from the open-label...

18:00
SilkTech Biopharmaceuticals, a company devoted to improving eye health through the development of silk-derived protein biotherapeutics for the targeted treatment of Dry Eye Disease (DED), today announced the company has received clearance of its...

14:56
HonorHealth Research Institute announced that the first patients have been enrolled in the SynIVUS-DAPT Study, a clinical study designed to test outcomes of decreasing the amount of time patients, with a high risk of bleeding, take antiplatelet...

14:40
One of the mechanisms that makes so-called triple-negative breast cancer (TNBC) notoriously aggressive and hard to treat is its ability to disarm proteins that suppress tumors and mutate them into tumor drivers. Seeking to better understand this...

13:25
With World Hemophilia Day approaching on April 17th, Israel's Sheba Medical Center, Tel HaShomer is making significant progress in the global battle to cure this bleeding disorder. More than 400,000 individuals suffer from hemophilia worldwide. Sheba...

13:04
Antibiotic resistance has been called one of the biggest public health threats of our time. There is a pressing need for new and novel antibiotics to combat the rise in antibiotic-resistant bacteria worldwide. Researchers from FIU's Herbert Wertheim...

10:23
Featuring an audience of over 1,200 attendees and a lineup of renowned speakers, the first day of the Annual Muscular Dystrophy Association (MDA) Clinical and Scientific Conference exemplified the meeting's theme of "Progress in Motion" by...

10:13
Natera, Inc. , Cancer Research UK, Imperial College London and the University of Leicester, today announced the publication of results of a clinical study demonstrating that the Signateratm research-use-only (RUO) molecular residual disease (MRD)...

10:00
The FX 635 low-level laser therapy device is now exclusively offered by Chiropractor Dr. Steven Shoshany at his lower Manhattan practice. Dr. Shoshany introduced this device to his practice at the beginning of 2019 in a limited, but practical role....

08:55
A new study in the April 2019 issue of JNCCN?Journal of the National Comprehensive Cancer Network  from the Abramson Cancer Center at the University of Pennsylvania found that cancer patients who kept ice chips in their mouths (termed 'oral...

08:30
AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, childhood onset neurogenetic disorders with limited or no treatment options, today announced the presentation of a new clinician-completed rating scale to...

08:00
Viracta Therapeutics, Inc. announced today that the U.S. Food & Drug Administration (FDA) has granted Orphan Drug Designations (ODD) to their Phase 2 drug candidate, nanatinostat, in combination with the antiviral valganciclovir, for the treatment of...

08:00
With the recent legalization of recreational cannabis in Canada, a major gap has been revealed, and that is a lack of scientific research on the health effects of its use ? both on the recreational and medical side. The research partnership between...

07:00
Transparency Life Sciences (TLS), the world's first all-digital drug development services company, today announced the successful completion of its VISITOR (VIrtual, SIteless, Technology Open Research) clinical trial. VISITOR was designed to assess...

07:00
Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.  , announced today the initiation of pre-clinical studies for BMC-121 & BMC-127, two rationally-designed microbial...

04:50
CStone Pharmaceuticals (the "Company" or "CStone"; HKEX: 2616) announces that the first patient has been successfully enrolled and dosed in a Phase III clinical trial assessing CS1001, China's first fully human, full-length anti-PD-L1 antibody, in...

03:30
AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, childhood onset neurogenetic disorders with limited or no treatment options, today announced the presentation of a new clinician-completed rating scale to...


15 april 2019

19:15
Tessa Therapeutics, a clinical-stage immunotherapy company focused on autologous and off-the-shelf, allogeneic therapies targeting solid tumors, today announced that it has...

1 2 3 4 5 6 7 8 9 10